- Home
- AXS vs NUVL Comparison
AXS vs NUVL Comparison
Compare AXS & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AXS | NUVL |
|---|---|---|
| Founded | 2001 | 2017 |
| Country | Bermuda | United States |
| Employees | 1876 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.0B | 7.8B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AXS | NUVL |
|---|---|---|
| Price | $100.69 | $97.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 15 |
| Target Price | $121.86 | ★ $135.33 |
| AVG Volume (30 Days) | ★ 461.3K | 441.5K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.77% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.16 | N/A |
| Revenue Next Year | $7.44 | $1,064.25 |
| P/E Ratio | $8.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $84.81 | $55.54 |
| 52 Week High | $110.34 | $113.02 |
Technical Indicators
Market Signals| Indicator | AXS | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 44.17 | 41.83 |
| Support Level | $98.77 | $73.22 |
| Resistance Level | $103.58 | $107.13 |
| Average True Range (ATR) | 1.91 | 3.39 |
| MACD | -0.21 | -0.38 |
| Stochastic Oscillator | 31.87 | 26.94 |
Price Performance
Historical ComparisonAbout AXS Axis Capital Holdings Limited
Axis Capital Holdings Ltd is a specialty underwriter and provider of insurance and reinsurance solutions with operations in Bermuda, the United States ("U.S."), Europe, Singapore, and Canada. The company manages its portfolio holistically, aiming to construct an optimum consolidated portfolio of funded and unfunded risks. The company's segment consists of AXIS Insurance and AXIS Reinsurance. The company generates the majority of its revenue from the Insurance segment. Geographically, the company generates the majority of its revenue from the United States.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.